NovoPro
Cart 2
  • Anti-EGFR/HER1/ErbB1 antibody
  • Anti-EGFR/HER1/ErbB1 antibody
  • Anti-EGFR/HER1/ErbB1 antibody

Anti-EGFR/HER1/ErbB1 antibody

Cat.#: 100135

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-EGFR/HER1/ErbB1 antibody
  • Documents
  • Description
    Rabbit polyclonal to EGFR/HER1/ErbB1
  • Tested applications
    ELISA, IHC-P
  • Species reactivity
    Human EGFR / HER1 / ErbB1
  • Alternative names
    ERBB antibody; HER1 antibody; mENA antibody; ERBB1 antibody; PIG61 antibody; NISBD2 antibody; Wa5 antibody; wa2 antibody; Erbb antibody; Errp antibody; wa-2 antibody; Errb1 antibody; AI552599 antibody; 9030024J15Rik antibody; 9030024J15Rik antibody; AI552599 antibody; EGFR antibody; Egfr antibody; Egfr antibody; ERBB antibody; Erbb antibody; ERBB1 antibody; ERBB1 antibody; ErbB-1 antibody; Errp antibody; Errp antibody; HER1 antibody; mENA antibody; PIG61 antibody; RP23-295E4.1 antibody; wa2 antibody; wa-2 antibody; Wa5 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    Produced in rabbits immunized with purified, recombinant Human EGFR / HER1 / ErbB1 (rh EGFR / HER1 / ErbB1; NP_005219; Met668-Ala1210). EGFR / HER1 / ErbB1 specific IgG was purified by Human EGFR / HER1 / ErbB1 affinity chromatography.
  • Clonality
    Polyclonal
  • Formulation
    0.2 μm filtered solution in PBS
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    ELISA: 0.1-0.2 μg/ml

    This antibody can be used at 0.1-0.2 μg/ml with the appropriate secondary reagents to detect Human EGFR / HER1 / ErbB1. The detection limit for Human EGFR / HER1 / ErbB1 is approximately 0.039 ng/well.

    IHC-P: 0.1-2 μg/ml

  • Validations

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    Immunochemical staining of human EGFR in human colon carcinoma with rabbit polyclonal antibody (1 µg/mL,formalin-fixed paraffin embedded sections).

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    Immunochemical staining of human EGFR in human ovarian cancer with rabbit polyclonal antibody (1 µg/mL,formalin-fixed paraffin embedded sections).

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    EGFR / HER1 / ErbB1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    Immunochemical staining of human EGFR in human placenta with rabbit polyclonal antibody (1 µg/mL,formalin-fixed paraffin embedded sections). Positive staining was localized to trophoblast.

  • Background
    As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF-α, betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.
  • References
    • Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2): 211-25.
    • Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann. Oncol. 16(4): 538-48.
    • Yarden, Y., et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2(2): 127-37.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"